459434-39-0

Basic information

• Product Name: 3-AMINO-N-CYCLOPROPYLBENZENESULFONAMIDE
• Synonyms: N-CYCLOPROPYL 3-AMINOBENZENESULFONAMIDE;3-AMINO-N-CYCLOPROPYLBENZENESULFONAMIDE;N-Cyclopropyl 3-Aminophenylsulfonamide;3-Amino-N-cyclopropylbenzenesulphonamide;benzenesulfonamide, 3-amino-N-cyclopropyl-;3-Amino-N-cyclopropylbenzenesulphonamide 97%;3-Amino-N-cyclopropylbenzenesulphonamide97%
• CAS NO: 459434-39-0
• Molecular Formula: C₉H₁₂N₂O₂S
• Molecular Weight: 212.27
• Product Categories: Amines;blocks;Sulfonamides;Acids and Derivatives;Amines and Anilines;API intermediates
• Mol File: 459434-39-0.mol

Chemical Properties

• Boiling Point: 416.5 °C at 760 mmHg
• Flash Point: 205.7 °C
• Appearance: /
• Density: 1.39 g/cm³
• Vapor Pressure: 3.79E-07mmHg at 25°C
• Refractive Index: 1.637
• Storage Temp.: Keep cold
• PKA: 12.04±0.20(Predicted)
• CAS DataBase Reference: 3-AMINO-N-CYCLOPROPYLBENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-N-CYCLOPROPYLBENZENESULFONAMIDE(459434-39-0)
• EPA Substance Registry System: 3-AMINO-N-CYCLOPROPYLBENZENESULFONAMIDE(459434-39-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 459434-39-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-N-cyclopropylbenzenesulfonamide is used as a pharmaceutical intermediate for the development of various drugs. Its benzenesulfonamide moiety is known to exhibit biological activities, making it a valuable component in the synthesis of new pharmaceutical compounds.
Used in Chemical Industry:
In the chemical industry, 3-Amino-N-cyclopropylbenzenesulfonamide serves as a key building block for the synthesis of other organic compounds. Its unique molecular structure, featuring an aromatic benzene ring and a cyclopropyl group, allows for the creation of a wide range of chemical products with diverse applications.
Used in Antibacterial Applications:
3-Amino-N-cyclopropylbenzenesulfonamide is used as an antibacterial agent due to the biological activity of its benzenesulfonamide moiety. It can be incorporated into the development of new antibiotics to combat bacterial infections.
Used in Diuretic Applications:
3-AMINO-N-CYCLOPROPYLBENZENESULFONAMIDE is also used in the development of diuretic drugs, which help increase urine production and promote the removal of excess water and salts from the body. The benzenesulfonamide group in 3-Amino-N-cyclopropylbenzenesulfonamide contributes to its diuretic properties.
Used in Antidiabetic Applications:
3-Amino-N-cyclopropylbenzenesulfonamide is utilized in the development of antidiabetic drugs, which help regulate blood sugar levels in individuals with diabetes. Its benzenesulfonamide moiety is known to possess antidiabetic properties, making it a valuable component in the synthesis of such medications.

InChI:InChI=1/C9H12N2O2S/c10-7-2-1-3-9(6-7)14(12,13)11-8-4-5-8/h1-3,6,8,11H,4-5,10H2

Upstream product

• 121-51-7 3-nitrobenzenesulphonyl chloride 
• 401589-92-2 N-cyclopropyl-3-nitrobenzenesulfonamide 

Downstream Products

• 474711-07-4 1-[3-(cyclopropylaminosulfonyl)phenyl]piperazine 
• 1403818-79-0 N-cyclopropyl-3-((5-(thiophen-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)benzenesulfonamide 
• 1445879-61-7 N-cyclopropyl-4-((3-(N-cyclopropylsulfamoyl)phenyl)amino)-7-(2,4-dimethoxypyrimidin-5-yl)quinoline-3-sulfonamide 

Relevant articles and documents

SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, or P(O)R1cR1c; or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.

NITROGENOUS FUSED?RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF

The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. Inparticular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, X represents a nitrogen-containing condensed aromatic heterocyclic group such as imidazo[1,2-a]pyridine, benzimidazole, quinazoline, quinoline, or 2,1-benzisoxazole and has (R4)n as substituent groups; Y represents a C3-8 cycloalkyl group, C4-8 cycloalkenyl group, 5- to 14-membered non-aromatic heterocyclic group, C6-14 aromatic hydrocarbon cyclic group or 5- to 14-membered aromatic heterocyclic group; n in (R4)n is 0, 1, 2 or 3, and Z groups independently represent (1) hydrogen atom, (2) amino group, (3) halogen atom, (4) hydroxyl group, (5) nitro group, (6) cyano group, (7) azido group, (8) formyl group, (9) hydroxyamino group, (10) sulfamoyl group, (11) guanodino group, (12) oxo group, (13) C2-6 alkenyl group, (14) C1-6 alkoxy group, (15) C1-6 alkylhydroxyamino group, (16) halogenated C1-6 alkyl group, (17) halogenated C2-6 alkenyl group, (18) (i) C3-7cycloalkyl group, (ii) C3-7cycloalkenyl group, (iii) 5- to 14-membered non-aromatic heterocyclic group, each of which may have one or more substituent groups Q, or (19) formula -M1-M2-M3, R1 represents (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) nitro group, (5) cyano group, (6) halogenated C1-6 alkyl group, (7) C2-6 alkyl group substituted with a hydroxyl or cyano group, (8) C2-6 alkenyl group, or (9) formula -L1-L2-L3, and R2 represents a hydrogen atom or a protecting group; and R3 represents a hydrogen atom, halogen atom, cyano group, amino group, C1-4 alkyl group or halogenated C1-4 alkyl group.